Cargando…

mRNA vaccine development for cholangiocarcinoma: a precise pipeline

Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases, however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Tian-Yu, Huang, Xing, Zhang, Gang, Lu, Ming-Hao, Liang, Ting-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277828/
https://www.ncbi.nlm.nih.gov/pubmed/35821067
http://dx.doi.org/10.1186/s40779-022-00399-8
_version_ 1784746065074847744
author Tang, Tian-Yu
Huang, Xing
Zhang, Gang
Lu, Ming-Hao
Liang, Ting-Bo
author_facet Tang, Tian-Yu
Huang, Xing
Zhang, Gang
Lu, Ming-Hao
Liang, Ting-Bo
author_sort Tang, Tian-Yu
collection PubMed
description Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases, however, its application in CHOL is limited due to the thoughtlessness in the integration of vaccine design and patient selection. A recent study established an integrated path for identifying potent CHOL antigens for mRNA vaccine development and a precise stratification for identifying CHOL patients who can benefit from the mRNA vaccines. In spite of a promising prospect, further investigations should identify immunogenic antigens and onco-immunological characteristics of CHOL to guide the clinical application of CHOL mRNA vaccines in the future.
format Online
Article
Text
id pubmed-9277828
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92778282022-07-14 mRNA vaccine development for cholangiocarcinoma: a precise pipeline Tang, Tian-Yu Huang, Xing Zhang, Gang Lu, Ming-Hao Liang, Ting-Bo Mil Med Res Perspective Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases, however, its application in CHOL is limited due to the thoughtlessness in the integration of vaccine design and patient selection. A recent study established an integrated path for identifying potent CHOL antigens for mRNA vaccine development and a precise stratification for identifying CHOL patients who can benefit from the mRNA vaccines. In spite of a promising prospect, further investigations should identify immunogenic antigens and onco-immunological characteristics of CHOL to guide the clinical application of CHOL mRNA vaccines in the future. BioMed Central 2022-07-12 /pmc/articles/PMC9277828/ /pubmed/35821067 http://dx.doi.org/10.1186/s40779-022-00399-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Perspective
Tang, Tian-Yu
Huang, Xing
Zhang, Gang
Lu, Ming-Hao
Liang, Ting-Bo
mRNA vaccine development for cholangiocarcinoma: a precise pipeline
title mRNA vaccine development for cholangiocarcinoma: a precise pipeline
title_full mRNA vaccine development for cholangiocarcinoma: a precise pipeline
title_fullStr mRNA vaccine development for cholangiocarcinoma: a precise pipeline
title_full_unstemmed mRNA vaccine development for cholangiocarcinoma: a precise pipeline
title_short mRNA vaccine development for cholangiocarcinoma: a precise pipeline
title_sort mrna vaccine development for cholangiocarcinoma: a precise pipeline
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277828/
https://www.ncbi.nlm.nih.gov/pubmed/35821067
http://dx.doi.org/10.1186/s40779-022-00399-8
work_keys_str_mv AT tangtianyu mrnavaccinedevelopmentforcholangiocarcinomaaprecisepipeline
AT huangxing mrnavaccinedevelopmentforcholangiocarcinomaaprecisepipeline
AT zhanggang mrnavaccinedevelopmentforcholangiocarcinomaaprecisepipeline
AT luminghao mrnavaccinedevelopmentforcholangiocarcinomaaprecisepipeline
AT liangtingbo mrnavaccinedevelopmentforcholangiocarcinomaaprecisepipeline